Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julio C Chavez

Showing results (21-30 of 132) with videos related to

Pageof 14
Sort By:
Immunotargets and Therapy|November 23, 2019
Cytokine Release Syndrome: Current PerspectivesHemant Murthy, Madiha Iqbal, Julio C Chavez, et al.
Cancer Control : Journal of the Moffitt Cancer Center|May 22, 2018
Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and TreatmentLuis Miguel Juárez-Salcedo, Lubomir Sokol, Julio C Chavez, et al.
Expert Opinion on Biological Therapy|December 12, 2025
Bispecific antibody combination regimens for B-cell non-Hodgkin's lymphomasKhushali Jhaveri, Aditi Saha, Luis Miguel Juarez-Salcedo, et al.
International Journal of Hematologic Oncology|September 20, 2021
Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directionsJulio C Chavez, Farah Yassine, Jose Sandoval-Sus, et al.
Therapeutics and Clinical Risk Management|June 19, 2018
Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphomaMichael D Jain, Christina A Bachmeier, Vania H Phuoc, et al.
Expert Review of Anticancer Therapy|January 20, 2023
Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphomaRazan Mohty, Yenny Moreno Vanegas, Julio C Chavez, et al.
Current Research in Translational Medicine|August 20, 2020
Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trialsFarah Yassine, Madiha Iqbal, Hemant Murthy, et al.
Cancer|July 12, 2008
Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemiaMohamed A Kharfan-Dabaja, Julio C Chavez, Khadija A Khorfan, et al.
Expert Review of Hematology|February 3, 2015
CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic optionsJorge J Castillo, Julio C Chavez, Francisco J Hernandez-Ilizaliturri, et al.
Targeted Oncology|March 4, 2025
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative ReviewDavid B Miklos, Peter A Riedell, Alex Bokun, et al.
Pageof 14

Showing results (21-30 of 132) with videos related to

Sort By:
Pageof 14
Immunotargets and Therapy|November 23, 2019
Cytokine Release Syndrome: Current PerspectivesHemant Murthy, Madiha Iqbal, Julio C Chavez, et al.
Cancer Control : Journal of the Moffitt Cancer Center|May 22, 2018
Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and TreatmentLuis Miguel Juárez-Salcedo, Lubomir Sokol, Julio C Chavez, et al.
Expert Opinion on Biological Therapy|December 12, 2025
Bispecific antibody combination regimens for B-cell non-Hodgkin's lymphomasKhushali Jhaveri, Aditi Saha, Luis Miguel Juarez-Salcedo, et al.
International Journal of Hematologic Oncology|September 20, 2021
Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directionsJulio C Chavez, Farah Yassine, Jose Sandoval-Sus, et al.
Therapeutics and Clinical Risk Management|June 19, 2018
Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphomaMichael D Jain, Christina A Bachmeier, Vania H Phuoc, et al.
Expert Review of Anticancer Therapy|January 20, 2023
Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphomaRazan Mohty, Yenny Moreno Vanegas, Julio C Chavez, et al.
Current Research in Translational Medicine|August 20, 2020
Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trialsFarah Yassine, Madiha Iqbal, Hemant Murthy, et al.
Cancer|July 12, 2008
Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemiaMohamed A Kharfan-Dabaja, Julio C Chavez, Khadija A Khorfan, et al.
Expert Review of Hematology|February 3, 2015
CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic optionsJorge J Castillo, Julio C Chavez, Francisco J Hernandez-Ilizaliturri, et al.
Targeted Oncology|March 4, 2025
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative ReviewDavid B Miklos, Peter A Riedell, Alex Bokun, et al.
Pageof 14